Business Wire

Kymeta Welcomes Industry Leaders to Board of Advisors

14.1.2025 17:00:00 CET | Business Wire | Press release

Share

The world-leading flat-panel satellite antenna company, Kymeta (www.kymetacorp.com) announced today the addition of two new members to the Board of Advisors, James Geurts and Elizabeth Kimber.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114298718/en/

(Graphic: Business Wire)

The Honorable James Geurts, known to most as Hondo, has over three decades of leadership in the national security sector, including service as the Under Secretary of the Navy, the Department’s second-highest-ranking civilian, responsible for the effective global business operations of the U.S. Navy and Marine Corps team. From 2017 until 2021, after his Presidential Appointment and unanimous Senate confirmation, he served as the Assistant Secretary of the Navy for Research, Development and Acquisition. Since his retirement from government, Geurts has worked extensively to improve the Nation’s defense industrial base and mentors public and private sector teams on scalability, agility, innovation, teamwork, talent development, and leadership.

“Having dedicated much of my career to serving our nation and leading teams in complex, high-stakes environments, I am deeply honored to join Kymeta as a Board Advisor,” stated James Geurts. “Their commitment to innovation, operational excellence, and leadership aligns closely with the principles I have upheld throughout my service. I look forward to contributing my experience and insights to help drive the company's continued growth and success in serving its customers, stakeholders, and communities.”

Elizabeth (Beth) Kimber is a 37-year veteran of the Central Intelligence Agency (CIA) who culminated her career as the Deputy Director of CIA for Operations (DDO) and oversaw CIA’s worldwide HUMINT operations and covert action missions. She also served as Acting Deputy Director of CIA; Assistant Director of CIA for Europe and Eurasia; Deputy Director of the National Clandestine Service, and Chief, Special Operations Department, Counterterrorism Center. She spent 18 years in the field including in assignments as Chief of Station / DNI Representative. In 2022, Kimber joined Two Six Technologies as Vice President of Intelligence Community Strategy. She also serves on the ManTech Board of Directors.

“Having spent a career supporting national security, I am honored to be a part of Kymeta’s Board of Advisors and help showcase their cutting-edge technologies and solutions to national security partners,” said Elizabeth Kimber. “Kymeta has demonstrated a steadfast commitment to innovation, integrity, and driving meaningful impact in its industry. I look forward to leveraging my experience in intelligence, risk management, and organizational leadership to support the company’s mission and help guide its continued growth and success in an ever-evolving world.”

“We are thrilled to welcome Elizabeth and James to our Board of Advisors,” said Rick Bergman, CEO and President, Kymeta. “Their voice and expertise are perfectly suited for helping Kymeta advance our vision of securing the future with innovative technology. Their extensive backgrounds in defense and space sectors are perfectly suited to help guide our business to the next phase of growth.”

About Kymeta

Kymeta revolutionizes satellite communications through Intelligent Communications Platforms (ICPs). Founded in 2012 and headquartered in Redmond, Washington, Kymeta leverages cutting-edge metamaterial-based science to engineer, manufacture and deliver resilient connectivity and enhanced situational awareness for critical, mobile applications. Backed by U.S. and international patents our electronically steered flat panel antennas enable seamless communications on-the-move. With software-defined solutions, hybrid multi-network capabilities, and edge processing, we integrate satellite and cellular networks, ensuring continuous connectivity in challenging environments. Kymeta solutions serve government, military, maritime, transport, and public safety clients worldwide, providing uninterrupted connectivity and spatial intelligence anywhere, anytime. With over 150 patents, Kymeta is shaping the future of global communications, dedicated to delivering reliable, efficient, and intelligent connectivity solutions for an increasingly mobile and connected world.

For more information, visit kymetacorp.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250114298718/en/

null

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye